Banlangen Granules Anti-seasonal Influenza Study

Influenza Clinical Trial

— BLG  

Official title:

Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02232945
• Other study ID #: HWBY-001
• Status: Recruiting
• Phase: Phase 4
• First received: November 18, 2012
• Last updated: March 2, 2016
• Start date: April 2012
• Est. completion date: November 2016

Study information

• Verified date: March 2016
• Source: Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
• Contact: Yuedong Cai, Master
• Phone: 86-20-66282326
• Email: caiyuedong[@]813zy.com
• Is FDA regulated: No
• Health authority: China: Food and Drug AdministrationChina: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

This study aimed to evaluate the efficacy and safety of the nature herbal medicine Banlangen granules in patients infected with seasonal influenza A (H1N1,H3N2) and influenza B virus.

Description:

Inclusion criteria:

1. Patients have confirmed influenza A(H1N1,H3N2) or influenza B virus infection by real time PCR

2. age between 18-65 years old

3. axillary temperature ≥38ºC and with at least two constitutional symptoms (headache, chill, myalgia ，or fatigue) and one respiratory symptom (cough ，sore throat,or coryza) .

4. Illness onset had to be within 36 hours, and informed consent was obtained.

Exclusion criteria:

1. age younger than 18 or older than 65 years old.

2. patients confirmed with bronchitis, pneumonia,pleural effusion and interstitial lung disease by Chest imaging (chest X-ray or CT) .

3. Blood routine screening tests shows numeration of leukocyte 10.0×109/L or Neutrophil percentage ≥80%.

4. Those have got suppurative tonsillitis or cough purulent sputum.

5. Those with underling primary disorders, such as hematological disease, chronic obstructive pulmonary disease（FEV1/FVC＜70％，FEV1/ predicated value＜50％； or respiratory failure or right heart failure）， hepatic disease（ALT or AST≥triple ULN）, renal disease（Serum Creatinine＞2mg/dL）,chronic congestive heart failure( NYHA Ⅲ-IV)

7. Patient is allergic to the study medication(s). 8. Women who are pregnant or may possibly become pregnant or are lactating with a positive urine pregnant test, obesity (abody mass index (BMI) of 25 kg/m2 or more).

9. Those with immunodeficiency ,such as malignant tumor ; Organs or bone marrow transplantation ; AIDS ;or taking immune inhibitors during the last 3 months.

10. Doubt or does alcohol/drug abuse of history. 11. Those have participated in other clinical trial within three month before study randomization.

12. Two weeks before the test , those with acute respiratory Infection，otitis,or nasosinusitis .

13. Those already vaccinated or who will receive influenza vaccine. 14. other reasons not suitable for enrollment based on the investigator's discretion.

The primary efficacy endpoint:

1. The primary end point was the duration of illness which was defined as the time from onset of symptoms to the alleviation of the ten influenza-like symptoms including , nasal obstruction, running nose, cough, sore throat, headache, fatigue, myalgia, chills and sweating.

2. The time to defervescence, defined as the time from the first dose of study medication to the time when the body temperature declined to lower than 37.4ºC and was sustained for at least 24 hours.

Secondary efficacy endpoint:

The secondary end points included: 1) viral shedding duration, defined as the time from the illness onset to the first time the viral nucleic acid test was negative; 2) the severity of the disease,assessed by an area under the curve (AUC) analysis of a total of nine influenza-like symptom scores, the AUC was calculated as the product of the daily symptom scores times the duration of illness;3)frequency of Usage of Acetaminophen;4)and incidence of secondary complications of influenza, such as otitis, bronchitis, pneumonia，Nasosinusitis ,suppurative tonsillitis,acute parotitis，Reye'ssyndrome，central nervous system disease, Myocarditis and pericarditis, acute myositis, and toxic shock syndrome.5) economic evaluation.

Specimen:

the pharyngeal or the throat swab，blood. Pharyngea /throat secretions will be obtained from the upper respiratory tract of each patient.

All specimens will be stored at -80℃ in virus laboratory of the first affiliated hospital of guangzhou medical university for 5 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 177
• Est. completion date: November 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

with confirmed influenza A(H1N1,H3N2) or influenza B virus infection by real time RT-PCR (rRT-PCR), age between 18-65 years old, axillary temperature =38ºC and with at least two constitutional symptoms (headache, chill, myalgia ,or fatigue) and one respiratory symptom (cough ,sore throat,or coryza) . Illness onset had to be within 36 hours, and informed consent was obtained.

Exclusion Criteria:

1. age younger than 18 or older than 65 years old.

2. patients confirmed with bronchitis, pneumonia,pleural effusion and interstitial lung disease by Chest imaging (chest X-ray or CT) .

3. Blood routine screening tests shows numeration of leukocyte 10.0×109/L or Neutrophil percentage =80%.

4. Those have got suppurative tonsillitis or cough purulent sputum.

5. Those with underling primary disorders, such as hematological disease, chronic obstructive pulmonary disease(FEV1/FVC<70%,FEV1/ predicated value<50%; or respiratory failure or right heart failure), hepatic disease(ALT or AST=triple ULN), renal disease(Serum Creatinine>2mg/dL),chronic congestive heart failure( NYHA ?-IV)

7. Patient is allergic to the study medication(s). 8. Women who are pregnant or may possibly become pregnant or are lactating with a positive urine pregnant test, obesity (abody mass index (BMI) of 25 kg/m2 or more).

9. Those with immunodeficiency ,such as malignant tumor ; Organs or bone marrow transplantation ; AIDS ;or taking immune inhibitors during the last 3 months.

10. Doubt or does alcohol/drug abuse of history. 11. Those have participated in other clinical trial within three month before study randomization.

12. Two weeks before the test , those with acute respiratory Infection,otitis,or nasosinusitis .

13. Those already vaccinated or who will receive influenza vaccine. 14.other reasons not suitable for enrollment based on the investigator's discretion.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Drug:
• placebo of oseltamivir phosphate

• oseltamivir phosphate

• Banlangen (Radix Isatidis) granules

• placebo of Banlangen(Radix Isatidis) granules

Locations

Country	Name	City	State
China	Guangzhou Institute of Respiratory Disease	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited	Guangzhou Institute of Respiratory Disease

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improving the flu-like symptoms, such as fever etc	The primary end point was the duration of illness which was defined as the time from onset of symptoms to the alleviation of the ten influenza-like symptoms including , nasal obstruction, running nose, cough, sore throat, headache, fatigue, myalgia, chills and sweating.	21+7days	Yes
Primary	Improving the flu-like symptoms, such as fever etc	The time to defervescence, defined as the time from the first dose of study medication to the time when the body temperature declined to lower than 37.4ºC and was sustained for at least 24 hours.	21+7days	Yes
Secondary	others	viral shedding duration, defined as the time from the illness onset to the first time the viral nucleic acid test was negative	21+7days	Yes
Secondary	Others	the severity of the disease,assessed by an area under the curve (AUC) analysis of a total of nine influenza-like symptom scores, the AUC was calculated as the product of the daily symptom scores times the duration of illness	21+7days	Yes
Secondary	Others	frequency of Usage of Acetaminophen	21+7days	Yes
Secondary	Others	incidence of secondary complications of influenza	21+7days	Yes
Secondary	Others	economic evaluation	21+7days	Yes